by SignalFactory · October 18, 2021 | 10:11:57 UTC
Johnson & Johnson (NYSE: JNJ) is scheduled to report Q3 2021 results on, October 19 before the bell on Tuesday. In the previous report for Q2 in July, the company reported sales of $23.31 billion, an increase of 27.1% compared with $18.33 billion in the same quarter last year. Net profit was $6.28 billion, up 73.1% against $3.63 billion during the year-ago quarter. Diluted earnings per share (EPS) increased from $1.36 to $2.35. Adjusted diluted EPS rose 48.5% to $2.48 this year. This growth was driven by sales of various drugs, such as Stelara, Darzalex, Tremfya, Erleada, Imbruvica, and Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone palmitate).
In Q3, the earnings report is likely to be driven by the fast-growing healthcare business due to increased sales volume of medical devices, increased sales of its cancer drugs, Imbruvica and Darzalex, immunology drugs, Stelara and Tremfya, along with contributions from Covid-19 vaccines. With more than half of the US population fully vaccinated and at the international level vaccination rates are gradually increasing, this will bode well for J&J’s medical device business. However, there may be short-term margin pressures due to inflationary constraints and supply chain constraints. Also, since the Covid-19 vaccine is sold on a non-profit basis, this will have an impact on overall drug margins.
The good news, supporting the company’s upcoming sales and business development reports, is that the FDA and VRBPAC unanimously voted 19-0 to recommend an Emergency Use Authorization (EUA) for the approval of a booster dose of the Johnson & Johnson COVID-19 vaccine for adults 18 years of age and older at least two months after initial vaccination with a single-use vaccine. Voting is based on findings from the company’s two clinical trials, including the ENSEMBLE 2 Phase 3 study. Phase 3 clinical data and current world data, both suggest Johnson & Johnson COVID-19 vaccine disposables are strong and durable. The company anticipates a decision from the FDA on EUA amendments to booster doses of the Johnson & Johnson COVID-19 vaccine in the coming days and plans to submit relevant data to other regulators, the World Health Organization (WHO) and National Immunization Technical Advisory Groups (NITAGs) across the board to inform decision-making on local vaccine administration strategies, as needed.
EPS consensus estimate: According to Zacks Investment Research, based on 7 analyst forecasts, the consensus EPS forecast for the quarter was $2.37. The reported EPS for the same quarter last year was $2.2. Revenue is forecast to be $23.62 billion, up 12.1% from last year’s quarter, with the stock ranking at #4.
Johnson & Johnson Long (Buy) Enter at: 162.66 T.P_1: 171.41 T.P_2: 180.16 T.P_3: 186.39 S.L: 156.76
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user.
Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered.
While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all.
All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information.
All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way.
The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions.
Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company.
Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results.
Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.